The key catalyst is the ESMO 2026 presentation on October 23, where updated VMT-α-NET data will be presented. The Phase 3 site activation timeline around year-end is the next major binary event. Monitor cash burn rate — at $237M with current spending, the runway into late 2027 provides ample time but the quarterly cash burn is accelerating.
Price Chart
Executive Summary
Perspective Therapeutics reported Q2 2026 results with a net loss of $26.8M ($0.22/share), narrower than the $0.29 loss in the prior year quarter, but wider than the $21.5M net loss in Q2 2025. The company is advancing its lead program VMT-α-NET toward a Phase 3 study with site activation targeted around year-end 2026, and had approximately $237M in cash as of June 30, 2026, sufficient to fund operations into late 2027. The stock is likely to trade on the clinical pipeline progress and upcoming ESMO presentation rather than the financial results, which are typical for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $26.8M ($0.22/share) vs $21.5M ($0.29/share) in Q2 2025.
- Cash, cash equivalents, and short-term investments were approximately $237M as of June 30, 2026.
- VMT-α-NET advancing toward Phase 3 study; site activation targeted around year-end 2026.
- VMT-α-NET study update accepted for oral presentation at ESMO 2026 on October 23.
- 76 NETs patients treated across four cohorts as of July 31.
- R&D expenses were $21.5M for Q2 2026, up from $16.6M in Q2 2025.
- Chicago metro manufacturing site expected to complete construction in early 2027.
- Paul Lyne, Ph.D. appointed as Chief Science Officer in July 2026.
Financial Impact
Net loss of $26.8M in Q2 2026, compared to $21.5M in Q2 2025; cash burn rate remains elevated as R&D spending increased 30% YoY.
Risk Factors
- Clinical trial risks — VMT-α-NET Phase 3 may not meet endpoints or regulatory alignment may be delayed.
- Cash burn is increasing as R&D spending grows 30% YoY, potentially requiring future capital raises.
- Manufacturing site completion delays could impact Phase 3 supply readiness.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342495 |
| Document: catx-20260810.htm | 0001193125-26-342495 |
| Document: catx-ex99_2.htm | 0001193125-26-342495 |
| Document: 0001193125-26-342495-index-headers.html | 0001193125-26-342495 |
| Document: 0001193125-26-342495-index.html | 0001193125-26-342495 |
| Document: 0001193125-26-342495.txt | 0001193125-26-342495 |
| 8-K Data (Synthetic) | 0001193125-26-342495 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers